Biochemical effects of riluzole on Leishmania parasites

Experimental Parasitology

Volumn 133, Issue 3, 2013, Pages 250-254

  Guerrieri, Davide ^a,c   Ferrari, Stefania ^a   Costi, M Paola ^a   Michels, Paul A M ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b DE DUVE INSTITUTE   (Belgium)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Biopterin; Folate; Leishmania; Oxidative stress; Pteridine reductase; Riluzole

Indexed keywords

BIOPTERIN; OXIDOREDUCTASE; PTERIDINE REDUCTASE 1; PYRIMETHAMINE; RILUZOLE; UNCLASSIFIED DRUG;

ANTIPROTOZOAL ACTIVITY; ARTICLE; BIOCHEMISTRY; CELL CULTURE; CELL GROWTH; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SENSITIVITY; ENZYME ACTIVITY; GROWTH CURVE; IN VITRO STUDY; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

AMYOTROPHIC LATERAL SCLEROSIS; ANTICONVULSANTS; ANTIPROTOZOAL AGENTS; CELL LINE; ENZYME INHIBITORS; HUMANS; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; OXIDOREDUCTASES; PYRIMETHAMINE; RILUZOLE;

LEISHMANIA MAJOR; LEISHMANIA MEXICANA; PROTISTA;

EID: 84872451434     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2012.11.013     Document Type: Article

References (24)

1. Bello A.R., Nare B., Freedman D., Hardy L., Beverley S.M. PTR1: a reductase mediating salvage of oxidized pteridines and methotrexate resistance in the protozoan parasite Leishmania major. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:11442-11446.
2. Cavazzuti A., Paglietti G., Hunter W.N., Gamarro F., Piras S., Loriga M., et al. Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:1448-1453.
3. Chéramy A., Barbeito L., Godeheu G., Glowinski J. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neuroscience Letters 1992, 147:209-212.
4. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews 2006, 58:621-681.
5. Clayton C.E. Life without transcriptional control? From fly to man and back again. EMBO Journal 2002, 21:1881-1888.
6. Cruz A., Beverley S.M. Gene replacement in parasitic protozoa. Nature 1990, 348:171-173.
7. Cunningham M.L., Titus R.G., Turco S.J., Beverley S.M. Regulation of differentiation to the infective stage of the protozoan parasite Leishmania major by tetrahydrobiopterin. Science 2001, 292:285-287.
8. Ferrari S., Morandi F., Motiejunas D., Nerini E., Henrich S., Luciani R., et al. Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase. Journal of Medicinal Chemistry 2011, 54:211-221.
9. Hardy L.W., Matthews W., Nare B., Beverley S.M. Biochemical and genetic tests for inhibitors of Leishmania pteridine pathways. Experimental Parasitology 1997, 87:157-169.
10. Ivanetich K.M., Santi D.V. Dihydrofolate reductase-thymidylate synthase in protozoa. Experimental Parasitology 1990, 70:367-371.
11. Jackson J.E., Tally J.D., Ellis W.Y., Mebrahtu Y.B., Lawyer P.G., Were J.B., et al. Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania spp. from patients unresponsive to pentavalent antimony therapy. The American Journal of Tropical Medicine and Hygiene 1990, 43:464-480.
12. Linares G.E., Ravaschino E.L., Rodriguez J.B. Progresses in the field of drug design to combat tropical protozoan parasitic diseases. Current Medicinal Chemistry 2006, 13:335-360.
13. McConville M.J., de Souza D., Saunders E., Likic V.A., Naderer T. Living in a phagolysosome; metabolism of Leishmania amastigotes. Trends in Parasitology 2007, 23:368-375.
14. Mikus J., Steverding D. A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. Parasitology International 2000, 48:265-269.
15. Molyneux D.H., Killick-Kendrick R. Morphology ultrastructure and life cycles. The Leishmaniases in Biology and Medicine 1987, vol. 1:121-176. Academic Press Inc., London, (Chapter 2).
16. Moreira W., Leprohon P., Ouellette M. Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania. Cell Death & Disease 2011, 2011(2):e201. 10.1038/cddis.2011.83.
17. Nare B., Hardy L.W., Beverley S.M. The roles of pteridine reductase 1 and dihydrofolate reductase-thymidylate synthase in pteridine metabolism in the protozoan parasite Leishmania major. Journal of Biological Chemistry 1997, 272:13883-13891.
18. Nare B., Garraway L.A., Vickers T.J., Beverley S.M. PTR1-dependent synthesis of tetrahydrobiopterin contributes to oxidant susceptibility in the trypanosomatid protozoan parasite Leishmania major. Current Genetics 2009, 55:287-299.
19. Ouellette M., Drummerlsmith J., El Fadili A., Kundig C., Richard D., Roy G. Pterin transport and metabolism in Leishmania and related trypanosomatid parasites. International Journal of Parasitology 2002, 32:385-398.
20. Papadopoulou B., Roy G., Ouellette M. A novel antifolate resistance gene on the amplified H circle of Leishmania. EMBO Journal 1992, 11:3601-3688.
21. Scott D.A., Coombs G.H., Sanderson B.E. Folate utilisation by Leishmania species and the identification of intracellular derivatives and folate-metabolising enzymes. Molecular and Biochemical Parasitology 1987, 23:139-149.
22. Sienkiewicz N., Jarosławski S., Wyllie S., Fairlamb A.H. Chemical and genetic validation of dihydrofolate reductase-thymidylate synthase as a drug target in African trypanosomes. Molecular Microbiology 2008, 69:520-533.
23. Van Triest B., Pinedo H.M., Giaccone G., Peters G.J. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Annals of Oncology 2000, 11:385-391.
24. WHO Expert Committee The Leishmaniasis 1984, WHO, Geneva.